People on the Move
ImmunoGen
Biotech ImmunoGen has hired Eric Guempel as VP of product strategy and programme management.
Guempel joins the oncology firm, which specialising in antibody-drug conjugate (ADC) technology, from a role as head of new therapies and strategy for oncology at Merck Serono.
The new VP has over 30 years’ pharmaceutical experience, with a focus on new and cross-functional cancer therapeutics. In a previous position at Idec, he led the team developing Rituxan, and at Amgen he worked on Neupogen and Neulasta.
ImmunoGen manufactures ADCs in its own name and as a CMO. Its lead drug is Roche’s Kadcyla for advanced HER2-positive breast cancer.